Shares of Novo Nordisk and Eli Lilly slipped in premarket trading Wednesday after Roche said it had landed a $5.3 billion ...

Why some health groups are banding together to push for a range of obesity-care options in workplace-sponsored insurance.

Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to treat Type 2 diabetes. Some doctors also prescribe Mounjaro "off-label" for ...

Germany's financial markets watchdog is looking at whether Bayer fairly disclosed plans for shareholder approval of a capital ...

Injectable drugs like Ozempic and Wegovy may be new to most of the world, but the science behind them are familiar to those in the health field.

A real-world study of over 4,000 US patients without type 2 diabetes found that those who persisted with Tirzepatide for at ...

The biotech will commit $150 million to an alliance that hands it significant production capacity for a closely watched ...

Excess weight can trigger chronic low-grade inflammation, which has been linked to increased risk for conditions such as heart disease and dementia. GLP-1s work by suppressing appetite and making ...

We are looking into a health alert, as the FDA has ruled compounded versions of popular drugs used for weight loss will no longer be available.

The new FDA-approved weight loss medicines have changed the game for people with obesity, offering millions of Americans a ...

Secret playground Ozempic clubs are evolving as the next trend in dangerous, competitive dieting in schools, eating disorder ...

Roche is paying $1.65 billion in confirmed upfront fees to add to its burgeoning obesity pipelin | Roche is paying $1.65 ...